RVPH: the cash flow

MyFinsight

For the year ending 2025-12-31, RVPH had $962,461 increase in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Net loss	-19,864,902
Change in fair value of warrant liabilities	-89,010
Stock-based compensation expense	2,227,859
Prepaid clinical trial costs (current and non-current)	-540,601
Prepaid expenses and other current assets	-1,750
Accounts payable	-3,407,773
Accrued expenses and other current liabilities	-4,003,168
Net cash used in operating activities	-24,594,643
Proceeds from issuance of short-term debt	406,875
Repayment of short-term debt	458,154
Proceeds from issuance of common stock in atm offering, net of transaction costs-The Market Offering Agreement Atm Agreement	1,477,407
Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs	17,154,911
Proceeds from exercise of common stock warrants-Common Stock Warrants	6,976,065
Net cash provided by financing activities	25,557,104
Net decrease in cash and cash equivalents	962,461
Cash and cash equivalents, beginning of period	13,476,331
Cash and cash equivalents, end of period	14,438,792

Unit: Dollar.